{"id":580392,"date":"2021-12-28T12:24:02","date_gmt":"2021-12-28T12:24:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=580392"},"modified":"2021-12-28T12:24:02","modified_gmt":"2021-12-28T12:24:02","slug":"achondroplasia-key-companies-and-pipeline-landscape-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/achondroplasia-key-companies-and-pipeline-landscape-analysis-by-delveinsight_580392.html","title":{"rendered":"Achondroplasia Key Companies and Pipeline Landscape Analysis by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1640666135.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Achondroplasia Key Companies and Pipeline Landscape Analysis by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1640666135.png\" alt=\"Achondroplasia Key Companies and Pipeline Landscape Analysis by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Achondroplasia Pipeline<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">There are 5+ companies working in the Achondroplasia pipeline landscape.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/achondroplasia-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Achondroplasia pipeline report<\/a><\/strong> covers the emerging drugs profiles, including clinical and nonclinical products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Highlights from the Achondroplasia Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>There are <strong>5+ drugs<\/strong> in the Achondroplasia pipeline.<\/li>\n<li>The Achondroplasia pipeline consists of therapies in different clinical phase stages, including <strong>Vosoritide, Recifercept, RBM-007,<\/strong> and others.<\/li>\n<li>Leading players actively working to improve the Achondroplasia treatment landscape are <strong>BioMarin, Pfizer, Ribomic Inc.,<\/strong> and others.<\/li>\n<li><strong>Recifercept<\/strong> is a <strong>Pfizer<\/strong> asset acquired from Therachon Holdings. In 2019, Pfizer paid <strong>USD 360 million<\/strong> for Therachon, a privately-held clinical-stage biotech company, capturing assets such as Recifercept.<\/li>\n<li>Achondroplasia therapies in the late stage of development include <strong>Vosoritide (BioMarin)<\/strong> and others.<\/li>\n<li><strong>RBM-007<\/strong> is being developed and invested in the early stage of development by <strong>Ribomic Inc.<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Get a detailed analysis of the pipeline landscape @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/achondroplasia-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Achondroplasia Pipeline Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Achondroplasia Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Achondroplasia is a rare genetic disorder that causes short-limb skeletal dysplasia in about 1 in 20,000-30,000 live births. This genetic disorder is caused by a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene, which occurs as a result of either a spontaneous genetic mutation (in 80% of patients) or an inherited genetic mutation (in 20% of patients).<\/p>\n<p style=\"text-align: justify;\"><strong>Achondroplasia Symptoms<\/strong><\/p>\n<p style=\"text-align: justify;\">Achondroplasia patients experience the following symptoms:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Exceptionally large head (macrocephaly)<\/li>\n<li>Short stature and short upper arms (rhizomelic dwarfism) (adult height of approximately 4 feet)<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Achondroplasia Pipeline Analysis: Drug Profiles<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Recifercept (TA 46): Pfizer<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Product Description<\/strong><\/p>\n<p style=\"text-align: justify;\">Recifercept (TA 46) is a soluble recombinant human fibroblast growth factor receptor 3 (FGFR3) decoy with an MOA are Achondroplasia treatmentsexpected to normalize the overactive FGFR3 signaling pathways that underpin achondroplasia-related bone development abnormalities.<\/p>\n<p style=\"text-align: justify;\"><strong>Phase II<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>NCT04638153:<\/strong> Pfizer launched a Phase II trial titled &#8220;A Phase II multiple dose, randomized study to assess the safety, tolerability, pharmacokinetics, and efficacy of Refercept in children with Achondroplasia&#8221; in December 2020.<\/p>\n<p style=\"text-align: justify;\"><strong>Achondroplasia Pipeline Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Vosoritide: BioMarin<\/li>\n<li>Recifercept: Pfizer<\/li>\n<li>RBM-007: Ribomic Inc.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Find out the emerging therapies and companies @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/achondroplasia-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Achondroplasia Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Achondroplasia Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>By Product Type<\/strong><\/li>\n<ul>\n<li>Monotherapy<\/li>\n<li>Combination Therapy<\/li>\n<\/ul>\n<li><strong>By Stage<\/strong><\/li>\n<ul>\n<li>Discovery<\/li>\n<li>Pre-Clinical<\/li>\n<li>Phase I<\/li>\n<li>Phase II<\/li>\n<li>Phase III<\/li>\n<li>Pre-registration<\/li>\n<\/ul>\n<li><strong>By Route of Administration<\/strong><\/li>\n<ul>\n<li>Inhalation<\/li>\n<li>Intravenous<\/li>\n<li>Oral<\/li>\n<li>Subcutaneous<\/li>\n<\/ul>\n<li><strong>By Molecule Type<\/strong><\/li>\n<ul>\n<li>Small Molecule<\/li>\n<li>Stem Cell Therapy<\/li>\n<li>Gene Therapy<\/li>\n<\/ul>\n<li><strong>Targets<\/strong><\/li>\n<ul>\n<li>Immune System<\/li>\n<li>Multiple Kinase<\/li>\n<\/ul>\n<li><strong>By Mechanism of Action<\/strong><\/li>\n<ul>\n<li>Protease Inhibitors<\/li>\n<li>Immunomodulatory<\/li>\n<\/ul>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Scope of the Report<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Coverage:<\/strong> Global<\/p>\n<p style=\"text-align: justify;\"><strong>Achondroplasia Key Players:<\/strong> BioMarin, Pfizer, Ribomic Inc., among others<\/p>\n<p style=\"text-align: justify;\"><strong>Achondroplasia Pipeline Therapies:<\/strong> Vosoritide, Recifercept, RBM-007, and others<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<table border=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td>\n<p>1.<\/p>\n<\/td>\n<td>\n<p>Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>2.<\/p>\n<\/td>\n<td>\n<p>Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>3.<\/p>\n<\/td>\n<td>\n<p>Achondroplasia: Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>4.<\/p>\n<\/td>\n<td>\n<p>Achondroplasia &#8211; Analytical Perspective In-depth Commercial Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>5.<\/p>\n<\/td>\n<td>\n<p>Pipeline Therapeutics<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>6.<\/p>\n<\/td>\n<td>\n<p>Late Stage Products (Phase III)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>7.<\/p>\n<\/td>\n<td>\n<p>Mid Stage Products (Phase II)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>8.<\/p>\n<\/td>\n<td>\n<p>Early Stage Products (Phase I)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>9.<\/p>\n<\/td>\n<td>\n<p>Pre-clinical and Discovery Stage Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>10.<\/p>\n<\/td>\n<td>\n<p>Therapeutic Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>11.<\/p>\n<\/td>\n<td>\n<p>Inactive Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>12.<\/p>\n<\/td>\n<td>\n<p>Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>13.<\/p>\n<\/td>\n<td>\n<p>Achondroplasia Key Companies&nbsp;<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>14.<\/p>\n<\/td>\n<td>\n<p>Achondroplasia&nbsp; Key Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>15.<\/p>\n<\/td>\n<td>\n<p>Achondroplasia Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>16.<\/p>\n<\/td>\n<td>\n<p>Achondroplasia Market Drivers and Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>17.<\/p>\n<\/td>\n<td>\n<p>Achondroplasia Future Perspectives and Conclusion<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>18.<\/p>\n<\/td>\n<td>\n<p>Achondroplasia Analyst Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>19.<\/p>\n<\/td>\n<td>\n<p>Appendix<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">Get in touch with our business executive for <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Healthcare Due Diligence Services<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key questions answered in the Achondroplasia Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>What Achondroplasia treatments are available?<\/li>\n<li>How many pharmaceutical companies are working on treatments for Achondroplasia?<\/li>\n<li>Which of these companies&#8217; pharmaceuticals is the most commonly used?<\/li>\n<li>How many Achondroplasia medications does each company manufacture?<\/li>\n<li>How many drugs are in the early, middle, or late stages of development aimed at Achondroplasia?<\/li>\n<li>How many can current therapies be used alone or in combination with others?<\/li>\n<li>What are the most significant Achondroplasia collaborations, mergers and acquisitions, and licensing strategies?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/achondroplasia-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Achondroplasia Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s <strong>&#8220;Achondroplasia &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221;<\/strong> report delivers an in-depth understanding of the Achondroplasia, historical and forecasted epidemiology, and the Achondroplasia market trends in the 7MM.<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=achondroplasia-key-companies-and-pipeline-landscape-analysis-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=achondroplasia-key-companies-and-pipeline-landscape-analysis-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Achondroplasia Pipeline There are 5+ companies working in the Achondroplasia pipeline landscape. DelveInsight&rsquo;s Achondroplasia pipeline report covers the emerging drugs profiles, including clinical and nonclinical products. It also covers the therapeutics assessment by product type, stage, route of administration, and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/achondroplasia-key-companies-and-pipeline-landscape-analysis-by-delveinsight_580392.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-580392","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/580392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=580392"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/580392\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=580392"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=580392"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=580392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}